ReviewFrontiers in pharmacology2020
A Review of the Effects of Natural Compounds, Medicinal Plants, and Mushrooms on the Gut Microbiota in Colitis and Cancer.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Machine Learning Approaches for Compound-Target Interaction Prediction: A Review.Foods (Basel, Switzerland) · 2026Review
- Evaluation of the Protective Effect of the Secondary Root's Extract and Partitions of Devil's Claw (International journal of preventive medicine · 2026Article
- Interplay of gut microbiota, immune cells and natural products in reshaping cancer immunotherapy.Frontiers in microbiology · 2026Review
- An ethnobotanical study on medicinal food plants used by the Kazakh people in Altay, Xinjiang, China.Journal of ethnobiology and ethnomedicine · 2025Article
- Production of Myco-Nanomaterial Products fromPharmaceutics · 2025Article
- The Role ofMolecules (Basel, Switzerland) · 2025Review
- The Gut Health Revolution: Herbs and Dietary Phytochemicals in Balancing Gut Microbiota for Optimal Human Health.Current pharmaceutical biotechnology · 2025Review
- Visnagin treatment attenuates DSS-induced colitis by regulating inflammation, oxidative, stress, and mucosal damage.Frontiers in veterinary science · 2025Article
- Treatment with onion bulb extract both prevents and reverses allergic inflammation in a murine model of asthma.Pharmaceutical biology · 2024Article
- Review
- An ethnobotanical survey on the medicinal and edible plants used by the Daur people in China.Journal of ethnobiology and ethnomedicine · 2024Article
- Effect of Polycan, a β-Glucan fromInternational journal of molecular sciences · 2023Article
- Natural-Product-Derived Adjunctive Treatments to Conventional Therapy and Their Immunoregulatory Activities in Triple-Negative Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- Zein as an Effective Carrier for Hesperidin Delivery Systems with Improved Prebiotic Potential.Molecules (Basel, Switzerland) · 2023Article
- Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Modulation of the Gut Microbiota with Prebiotics and Antimicrobial Agents fromFoods (Basel, Switzerland) · 2023Review
- Article
- Clinical Relevance of Gut Microbiota Alterations under the Influence of Selected Drugs-Updated Review.Biomedicines · 2023Review
- Feasibility of mixed herbal medicine for improving gastric function in an alcohol-induced gastritis model.Physical activity and nutrition · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human gastrointestinal tract harbors a diverse array of microorganisms that play fundamental roles in health and disease. Imbalance in the gut microbiota, namely dysbiosis, can lead to various diseases, including cancer and gastrointestinal tract disorders. Approaches to improve gut dysbiosis, such as dietary intervention, intake of probiotics, and fecal microbiota transplantation are emerging strategies to treat these diseases. Various medicinal botanicals have reported anti-cancer and/or anti-inflammatory properties. Preclinical studies have illustrated that some of these natural products are also capable to modulate the gut microbiota, suggesting their use as possible alternative approach to improve gut dysbiosis and thereby assist diseases treatment. In this review article, we have summarized the current knowledge on the effects of natural compounds, medicinal plants, and mushrooms on the gut microbiota in various cancers and colitis in preclinical animal models. Challenges towards the clinical use of these medicinal botanicals as modulators of the gut microbiota in cancer and colitis treatment are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.